Drug intelligence / Profile preview

ALVAC-RG rabies glycoprotein

Development stage: Unknown
Lead developer: Parent
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

ALVAC-RG rabies glycoprotein (vCP65) is a recombinant vaccine candidate that uses the canarypox virus (ALVAC) as a vector to express the rabies virus G glycoprotein. The vaccine is non-replicating in mammalian cells but expresses the target antigen, inducing an immune response without productive viral replication. It was developed as a safer alternative for immunization against rabies and has demonstrated safety and immunogenicity in preclinical studies and early-phase clinical trials. The primary indication is prevention of rabies infection[1][2][3][6].

Other names: canarypox-rabies recombinantALVAC rabies vaccine

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on ALVAC-RG rabies glycoprotein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALVAC-RG rabies glycoprotein.